Results · Apr-Jun 2026
Sun Pharma Advanced Research Company Q1 FY27 results
Sales grew 314% to ₹39.9 crore from ₹9.6 crore in Apr-Jun 2025.
Operating profit was −₹34 crore, an operating margin of −85.2% (up 455.1 points from a year ago).
The net loss narrowed to ₹20.8 crore from ₹51.9 crore.
Against Jan-Mar 2026: sales −98%, swings to a loss.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 39.9 | 9.6 | +314% |
| Operating profit (EBITDA) | -34.0 | -52.1 | n/m |
| Operating margin | −85.2% | −540.2% | +455.1 pts |
| Net profit | -20.8 | -51.9 | loss narrows |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.